Rebecca N Jerome1, Jill M Pulley2, Nila A Sathe3, Shanthi Krishnaswami4, Alyssa B Dickerson2, Katherine J Worley5, Maria F Lima6, Consuelo H Wilkins7. 1. Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: rebecca.jerome@vumc.org. 2. Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA. 6. School of Graduate Studies and Research, Meharry Medical College, Nashville, TN, USA. 7. Department of Medicine, Vanderbilt University Medical Center and Department of Internal Medicine, Meharry Medical College, Nashville, TN, USA.
Abstract
PURPOSE: Outcome differences driven by variation in Blacks' biologic response to treatment may contribute to persistent racial disparities in asthma morbidity and mortality. This review assessed systematic variation in β2 agonist treatment outcomes among Blacks compared to other groups. METHODS: We conducted a systematic review of studies reporting differential response to β2 agonists among Blacks, including studies identifying pharmacogenetic variants. RESULTS: Of 3158 papers, 20 compared safety or efficacy of β2 agonists among Blacks as compared with other subgroups. Six papers evaluating efficacy of short-acting β2 agonists (SABA) found similar or improved results among Blacks compared with other groups, while one small study found reduced response to SABA therapy among Blacks. Reports of safety and efficacy of long-acting β2 agonists (LABA) indicated similar results among Blacks in four papers, while four reports found reduced safety among Blacks, as compared with other groups. Four papers assessed genomic variation and relative treatment response in Blacks, with two finding significant effects of the p.Arg16Gly variant in ADRB2 on β2 agonist response and one finding significant gene-gene IL6/IL6R interaction effects on albuterol response. CONCLUSIONS: Evidence suggests the potential for differences in β2 agonist outcomes among Blacks compared with other groups. This literature, however, remains small and significantly underpowered for substantive conclusions. There are notable opportunities for adequately-powered investigations exploring safety and efficacy of β2 agonists among Blacks, including pharmacogenomic modifiers of response.
PURPOSE: Outcome differences driven by variation in Blacks' biologic response to treatment may contribute to persistent racial disparities in asthma morbidity and mortality. This review assessed systematic variation in β2 agonist treatment outcomes among Blacks compared to other groups. METHODS: We conducted a systematic review of studies reporting differential response to β2 agonists among Blacks, including studies identifying pharmacogenetic variants. RESULTS: Of 3158 papers, 20 compared safety or efficacy of β2 agonists among Blacks as compared with other subgroups. Six papers evaluating efficacy of short-acting β2 agonists (SABA) found similar or improved results among Blacks compared with other groups, while one small study found reduced response to SABA therapy among Blacks. Reports of safety and efficacy of long-acting β2 agonists (LABA) indicated similar results among Blacks in four papers, while four reports found reduced safety among Blacks, as compared with other groups. Four papers assessed genomic variation and relative treatment response in Blacks, with two finding significant effects of the p.Arg16Gly variant in ADRB2 on β2 agonist response and one finding significant gene-gene IL6/IL6R interaction effects on albuterol response. CONCLUSIONS: Evidence suggests the potential for differences in β2 agonist outcomes among Blacks compared with other groups. This literature, however, remains small and significantly underpowered for substantive conclusions. There are notable opportunities for adequately-powered investigations exploring safety and efficacy of β2 agonists among Blacks, including pharmacogenomic modifiers of response.
Authors: Cindy L J Weinstein; Nicholas Ryan; Tulin Shekar; Davis Gates; Stephen J Lane; Ioana Agache; Robert A Nathan Journal: J Allergy Clin Immunol Date: 2018-12-08 Impact factor: 10.793
Authors: Robert F Lemanske; David T Mauger; Christine A Sorkness; Daniel J Jackson; Susan J Boehmer; Fernando D Martinez; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Ronina A Covar; Theresa W Guilbert; Gary Larsen; Wayne J Morgan; Mark H Moss; Joseph D Spahn; Lynn M Taussig Journal: N Engl J Med Date: 2010-03-02 Impact factor: 91.245
Authors: Michael E Wechsler; Susan J Kunselman; Vernon M Chinchilli; Eugene Bleecker; Homer A Boushey; William J Calhoun; Bill T Ameredes; Mario Castro; Timothy J Craig; Loren Denlinger; John V Fahy; Nizar Jarjour; Shamsah Kazani; Sophia Kim; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Amy Markezich; Richard J Martin; Perdita Permaul; Stephen P Peters; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Michael J Walter; Stephen I Wasserman; Elliot Israel Journal: Lancet Date: 2009-11-21 Impact factor: 79.321
Authors: Michael E Wechsler; Barbara P Yawn; Anne L Fuhlbrigge; Wilson D Pace; Michael J Pencina; Gheorghe Doros; Shamsah Kazani; Benjamin A Raby; Jane Lanzillotti; Suzanne Madison; Elliot Israel Journal: JAMA Date: 2015-10-27 Impact factor: 56.272